TCVAX | VMVAX | TCVAX / VMVAX | |
Total Expense Ratio | 1.24 | 0.07 | 1,771% |
Annual Report Gross Expense Ratio | 1.50 | 0.07 | 2,143% |
Fund Existence | 16 years | 14 years | - |
Gain YTD | -2.279 | -1.539 | 148% |
Front Load | 5% | N/A | - |
Min. Initial Investment | 2500 | 3000 | 83% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 547M | 29.1B | 2% |
Annual Yield % from dividends | 0.56 | 2.40 | 24% |
Returns for 1 year | -5.03 | 3.63 | -139% |
Returns for 3 years | 1.12 | 15.72 | 7% |
Returns for 5 years | 43.21 | 76.66 | 56% |
Returns for 10 years | 33.02 | 75.91 | 43% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
NVD | 24.16 | 0.31 | +1.30% |
GraniteShares 2x Short NVDA Daily ETF | |||
PP | 26.10 | N/A | N/A |
Meet Kevin Pricing Power ETF (The) | |||
NOBL | 98.43 | -0.19 | -0.20% |
ProShares S&P 500 Dividend Aristocrats | |||
SEIQ | 35.00 | -0.17 | -0.47% |
SEI Enhanced US Large Cap Qual Fac ETF | |||
ARKG | 21.13 | -0.60 | -2.76% |
ARK Genomic Revolution ETF |